Hollow stent filled with a therapeutic agent formulation

• US 9,901,663 B2
• Filed: 05/01/2014
• Issued: 02/27/2018
• Est. Priority Date: 05/06/2013
• Status: Expired due to Fees

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Pacetti, Stephen D., Ding, Ni
• Primary Examiner(s): Lopez, Leslie
• Application Number:
  US14/267,620
• Publication Number:
  US 20140330365A1
• Time in Patent Office: 1,398 Days
• Field of Search: None
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61L 2300/00 Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/426 Immunomodulating agents, i.e. cytokines, interleukins, interferons
• CPC Class Codes: A61L 2300/604 Biodegradation
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 27/505 Stabilizers
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/022 Metals or alloys
• CPC Class Codes: A61L 31/143 Stabilizers
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: B65B 3/003 Filling medical containers such as ampoules, vials, syringes or the like
• CPC Class Codes: Y10T 29/49993 Filling of opening

Abstract

A composition for loading into a structural element of a stent, where the structural element is defined by a lumen and at least one opening to access the lumen. The composition may comprise a therapeutic agent, and a chelator, a precipitation agent, or a combination thereof. Medical devices, such as stents, with a structural element defined by a lumen and at least one opening to access the lumen, filled with the compositions are also described.

Claims

1. A medical device, the device comprising:

a device body comprising at least one structural element, the structural element comprising a lumen and at least one opening to access the lumen; and

a composition within the lumen, the composition comprising a therapeutic agent, and a metal ion stabilizer;

wherein the at least one structural element has walls, the walls forming an interior surface and the lumen being surrounded by the interior surface;

wherein the composition comprises at least 0.1 μ

g of the metal ion stabilizer/cm² of the interior surface surrounding the lumen and not more than 15 μ

g metal of the ion stabilizer/cm² of the interior surface surrounding the lumen;

and

wherein the medical device is a stent.

2. The medical device of claim 1, wherein the metal ion stabilizer comprises a metal chelator.

3. The medical device of claim 1, wherein the metal ion stabilizer comprises a precipitation agent.

4. The medical device of claim 1, wherein the device body is biostable.

5. The medical device of claim 1, wherein the device body is formed of a biostable metal selected from the group consisting of 316L stainless steel, CoNi MP35N, CoCr L-605, elgiloy, nitinol, FePtCr, and combinations thereof.

6. The medical device of claim 1, wherein the interior surface of the at least one structural element of the stent body is not electropolished, or a degree of electropolishing of the interior surface of the at least one structural element is less than the outer surface of the stent.

7. The medical device of claim 1, wherein the therapeutic agent belongs to a macrolide lactone family and the therapeutic agent contains a triene moiety.

8. The medical device of claim 1, wherein the therapeutic agent is selected from the group consisting of rapamycin, everolimus, Biolimus A9, umirolimus, ridaforolimus, tacrolimus, temsirolimus, pimecrolimus, novolimus, merilimus, zotarolimus, 40-O-(3-hydroxypropyl)rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazolylrapamycin, 40-epi-(N1-tetrazolyl)-rapamycin, and combinations thereof.

9. The medical device of claim 1, wherein the metal ion stabilizer comprises a chelator selected from the group consisting of ethylene diamine tetraacetic acid (EDTA), calcium disodium EDTA, EDTA with a counterion of potassium, EDTA with a counterion of ammonium, EDTA with a counterion of a quaternary ammonium compound, 2,3-dimereapto-1-propanesulfonic acid, dimercaptosuccinic acid, dimercaprol, desferrioxamine mesylate, alpha lipoic acid, nitrilotriacetate, penicillamine, thiamine tetrahydrofurfiuyl disulfide, deferiprone, deferasirox, kojic acid, bisphosphonates, 3-hydroxy-4-pyridinecarboxylic acid, 4-hydroxy-3-pyridinecarboxylic acid, 1,6-Dimethyl-4-hydroxy-3-pyridinecarboxylic acid, 4-hydroxy-2-methyl-3-pyridinecarboxylic acid, and combinations thereof.

10. The medical device of claim 1, wherein the metal ion stabilizer comprises a chelator selected from the group consisting of sodium ascorbate, desferrioxamine, malic acid, citric acid, succinic acid, sodium, calcium, and magnesium salts of malic acid, citric acid, and succinic acid, feralex-G, clioquinol, curcumin, epigallocatechin, 3-hydroxy-4-pyridinone, 3-hydroxy-4-pyridinecarboxylic acid, 4-hydroxy-3-pyridinecarboxylic acid, 1,6-Dimethyl-4-hydroxy-3-pyridinecarboxylic acid, 4-hydroxy-2-methyl-3-pyridinecarboxylic acid, and combinations thereof.

11. The medical device of claim 1, wherein the metal ion stabilizer comprises a precipitation agent selected from the group consisting of stearic acid, lauric acid, capric acid, and caprylic acid, and sodium, calcium, and magnesium salts thereof, and combinations thereof.

12. The medical device of claim 1, wherein a combination of the therapeutic agent and the metal ion stabilizer comprises at least 50 wt % of the composition, at least 70 wt % of the composition, or at least 90 wt % of the composition.

13. The medical device of claim 1, wherein at least 90% of the volume of the lumen is filled with the composition.

14. The medical device of claim 1, wherein the metal ion stabilizer is selected from the group consisting of 2,3-dimereapto-1-propanesulfonic acid, dimercaptosuccinic acid, dimercaprol, desferrioxamine mesylate, alpha lipoic acid, nitrilotriacetate, penicillamine, thiamine tetrahydrofurfiuyl disulfide, deferiprone, deferasirox, kojic acid, bisphosphonates, 3-hydroxy-4-pyridinecarboxylic acid, 4-hydroxy-3-pyridinecarboxylic acid, 1,6-Dimethyl-4-hydroxy-3-pyridinecarboxylic acid, 4-hydroxy-2-methyl-3-pyridinecarboxylic acid, desferrioxamine, succinic acid, sodium, calcium, and magnesium salts of succinic acid, feralex-G, clioquinol, curcumin, epigallocatechin, stearic acid, lauric acid, capric acid, and caprylic acid, and sodium, calcium, and magnesium salts of stearic acid, lauric acid, capric acid, and caprylic acid, and combinations thereof.

15. The medical device of claim 1, wherein the at least one opening comprises one or more side openings to access the lumen and allow the therapeutic agent to be released from the lumen, and the side openings one or more being only on the abluminal side of the medical device.

16. A stent comprising:

a plurality of interconnected structural elements comprising a metallic material, wherein at least some of the structural elements are annular and comprise an interior lumen;

and

a therapeutic agent and an additive disposed within the interior lumen(s);

wherein an inner surface of the annular structural element(s) is susceptible to release of metal ions which are capable of degrading the therapeutic agent;

wherein the additive is for protecting the therapeutic agent from degradation by the metal ions by rendering the metal ions unable to interact with the therapeutic agent;

wherein the additive is present at an amount of at least 0.1 μ

g/cm² of the inner surface and not more than 15 μ

g/cm² of the inner surface; and

wherein the additive is selected from the group consisting of 2,3-dimereapto-1-propanesulfonic acid, dimercaptosuccinic acid, dimercaprol, desferrioxamine mesylate, alpha lipoic acid, nitrilotriacetate, thiamine tetrahydrofurfiuyl disulfide, deferiprone, deferasirox, kojic acid, bisphosphonates, 3-hydroxy-4-pyridinecarboxylic acid, 4-hydroxy-3-pyridinecarboxylic acid, 1,6-Dimethyl-4-hydroxy-3-pyridinecarboxylic acid, 4-hydroxy-2-methyl-3-pyridinecarboxylic acid, desferrioxamine, succinic acid, sodium, calcium, and magnesium salts of succinic acid, feralex-G, clioquinol, epigallocatechin, 3-hydroxy-4-pyridinone, stearic acid, lauric acid, capric acid, and caprylic acid, and sodium, calcium, and magnesium salts of stearic acid, lauric acid, capric acid, and caprylic acid, and combinations thereof.

17. The stent of claim 16, wherein the therapeutic agent is degraded by not more than 5 wt % at the end of the shelf-life of the stent, and wherein the shelf-life of the stent is at least 6 months, at least 9 months, at least 12 months, at least 18 months, or at least 24 months.

18. The stent of claim 16, wherein the additive is selected from the group consisting of 2,3-dimereapto-1-propanesulfonic acid, dimercaptosuccinic acid, dimercaprol, desferrioxamine mesylate, alpha lipoic acid, nitrilotriacetate, thiamine tetrahydrofurfiuyl disulfide, deferiprone, deferasirox, kojic acid, 3-hydroxy-4-pyridinecarboxylic acid, 4-hydroxy-3-pyridinecarboxylic acid, 1,6-Dimethyl-4-hydroxy-3-pyridinecarboxylic acid, 4-hydroxy-2-methyl-3-pyridinecarboxylic acid, desferrioxamine, feralex-G, clioquinol, epigallocatechin, and combinations thereof.

19. The stent of claim 16, wherein the additive comprises kojic acid.

20. A stent comprising:

a plurality of interconnected structural elements comprising a metallic material, wherein at least some of the structural elements are annular and comprise an interior lumen;

and

a therapeutic agent and an additive disposed within the interior lumen(s);

wherein an inner surface of the annular structural element(s) is susceptible to release of metal ions which are capable of degrading the therapeutic agent;

wherein the additive is for protecting the therapeutic agent from degradation by the metal ions by rendering the metal ions unable to interact with the therapeutic agent;

wherein the additive is present at an amount of at least 0.1 μ

g/cm² of the inner surface and not more than 15 μ

g/cm² of the inner surface; and

wherein the annular structural elements comprising the interior lumen are tubes formed from tube stock with the interior lumen of essentially uniform cross-sectional area and the tubes comprising one or more side openings to access the interior lumen and allow the therapeutic agent to be released from the interior lumen, and the side openings have a cross-sectional area of not more than 10% of the cross-sectional area of the lumen of the tube stock from which the annular structural element was formed.

21. A method comprising:

providing a medical device having a structural element, the structural element comprising a lumen and at least one opening to access the lumen;

filling the lumen of the structural element with a composition comprising a therapeutic agent and a metal ion stabilizer;

wherein the at least one structural element has walls, the walls forming an interior surface, and the lumen being surrounded by the interior surface;

wherein the composition comprises at least 0.1 μ

g of the metal ion stabilizer/cm² of the interior surface surrounding the lumen and not more than 15 μ

g of the metal ion stabilizer/cm² of the interior surface surrounding the lumen;

and

wherein the medical device is a stent.

22. The medical of claim 21, wherein the metal ion stabilizer comprises a metal chelator.

23. The medical of claim 21, wherein the metal ion stabilizer comprises a precipitation agent.

24. The method of claim 21, wherein filling the lumen comprises forming a filling composition by executing a first operation comprising dissolving, dispersing, or both dissolving and dispersing the therapeutic agent in a solvent and dissolving, dispersing, or both dissolving and dispersing the metal ion stabilizer in the solvent, executing a second operation comprising placing the filling composition into the lumen, and executing a third operation comprising removing the solvent.

25. The method of claim 24, wherein the solvent comprises a solvent selected from the group consisting of n-hexane, n-heptane, octane, decane, ethyl ether, propyl ether, diisopropyl ether, butyl ether, diisobutyl ketone, and combinations thereof.